COVID-19远程医疗政策变化对丁丙诺啡治疗阿片类使用障碍的影响
该研究为美国退伍军人健康管理局的国家回顾性队列研究,采用中断时间序列分析,评估2020年3月COVID-19政策变化对丁丙诺啡治疗阿片类使用障碍的影响。结果显示,政策变化后接受丁丙诺啡治疗的患者数继续增加,但诊疗模式转向远程医疗,电话和视频访视占多数,90天保留率显著下降而用药天数显著增加。
要点
- 2020年3月政策变化后首月接受丁丙诺啡治疗的患者数立即增加265人,随后每月显著增加47人。
- 截至2021年2月,电话访视使用患者最多(50.2%;4456次),其次为视频访视(32.4%;2870次)和面访(17.4%;1544次)。
- 疫情期患者 demographic 特征与疫情前相似,但90天保留率从49.6%显著降至47.7%,用药天数从203.8显著增至208.7。
核心结论
- COVID-19政策变化后接受丁丙诺啡治疗的患者数继续增加,但诊疗服务转向远程医疗访视。
研究设计与样本
- 美国退伍军人健康管理局的国家回顾性队列研究,采用中断时间序列分析,比较2019年3月至2020年2月与2020年3月至2021年2月两个时期。
主要发现
- 接受丁丙诺啡治疗的患者数从2019年3月的13415人增至2021年2月的15339人。
- 疫情前每月显著增加103人;政策变化后首月立即增加265人,随后每月显著增加47人。
- 截至2021年2月,电话访视占50.2%(4456次),视频访视占32.4%(2870次),面访占17.4%(1544次)。
- 疫情期患者人口学特征与疫情前相似,但达到90天丁丙诺啡治疗保留的比例从49.6%显著降至47.7%,用药天数从203.8显著增至208.7。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors examined the impact of COVID-19-related policies reducing barriers to telehealth delivery of buprenorphine treatment for opioid use disorder (OUD) on buprenorphine treatment across different modalities (telephone, video, and in-person visits). METHODS: This was a national retrospective cohort study with interrupted time-series analyses to examine the impact of policy changes in March 2020 on buprenorphine treatment for OUD in the Veterans Health Administration, during the year before the start of the COVID-19 pandemic (March 2019 to February 2020) and during the first year of the pandemic (March 2020 to February 2021). The authors also examined trends in the use of telephone, video, and in-person visits for buprenorphine treatment and compared patient demographic characteristics and retention in buprenorphine treatment across the two periods. RESULTS: The number of patients receiving buprenorphine increased from 13,415 in March 2019 to 15,339 in February 2021. By February 2021, telephone visits were used by the most patients (50.2%; 4,456 visits), followed by video visits (32.4%; 2,870 visits) and in-person visits (17.4%; 1,544 visits). During the pre-pandemic period, the number of patients receiving buprenorphine increased significantly by 103 patients per month. After the COVID-19 policy changes, there was an immediate increase of 265 patients in the first month, and the number continued to increase significantly, at a rate of 47 patients per month. The demographic characteristics of patients receiving buprenorphine during the pandemic period were similar to those during the pre-pandemic period, but the proportion of patients reaching 90-day retention on buprenorphine treatment decreased significantly from 49.6% to 47.7%, while days on buprenorphine increased significantly from 203.8 to 208.7. CONCLUSIONS: The number of patients receiving buprenorphine continued to increase after the COVID-19 policy changes, but the delivery of care shifted to telehealth visits, suggesting that any reversal of COVID-19 policies must be carefully considered.
引用
- Lin LA, Zhang L, Kim HM, et al. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder. Am J Psychiatry. 2022. PMID: 35899380. doi:10.1176/appi.ajp.21111141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。